Literature DB >> 3520936

Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification.

L S Nielsen, P A Andreasen, J Grøndahl-Hansen, J Y Huang, P Kristensen, K Danø.   

Abstract

Mouse monoclonal antibodies were derived against a plasminogen activator inhibitor with a mol. wt. of approximately 54,000 (54 K) from the human fibrosarcoma cell line HT-1080. Screening for hybrids producing antibodies directed against the inhibitor was performed with enzyme-linked immunosorbent assay and SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting. Four clones of hybridomas producing IgG1 antibodies were further characterized. The inhibitor was purified approximately 50-fold to homogeneity from conditioned cell culture fluid with a yield of approximately 85% by a one-step procedure using Sepharose-conjugated monoclonal antibody. In the 125I-fibrin plate assay one of the antibodies neutralized the effect of the inhibitor on urokinase-type plasminogen activator. Two of the antibodies bound complexes between urokinase-type plasminogen activator and inhibitor while the remaining two antibodies did not. The antibodies could be used for immunocytochemical localization of the inhibitor in HT-1080 cells. All four antibodies cross-reacted with a plasminogen activator inhibitor derived from cultured human umbilical cord endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3520936

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  25 in total

1.  Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.

Authors:  Kenneth A Botkjaer; Sarah Fogh; Erin C Bekes; Zhuo Chen; Grant E Blouse; Janni M Jensen; Kim K Mortensen; Mingdong Huang; Elena Deryugina; James P Quigley; Paul J Declerck; Peter A Andreasen
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857

2.  Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library.

Authors:  Jan K Jensen; Anders Malmendal; Birgit Schiøtt; Sune Skeldal; Katrine E Pedersen; Leyla Celik; Niels Chr Nielsen; Peter A Andreasen; Troels Wind
Journal:  Biochem J       Date:  2006-11-01       Impact factor: 3.857

3.  Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.

Authors:  P Kristensen; C Pyke; L R Lund; P A Andreasen; K Danø
Journal:  Histochemistry       Date:  1990

4.  cDNA cloning of human plasminogen activator-inhibitor from endothelial cells.

Authors:  D Ginsburg; R Zeheb; A Y Yang; U M Rafferty; P A Andreasen; L Nielsen; K Dano; R V Lebo; T D Gelehrter
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

5.  Plasminogen activator inhibitor type 1 biosynthesis and mRNA level are increased by dexamethasone in human fibrosarcoma cells.

Authors:  P A Andreasen; C Pyke; A Riccio; P Kristensen; L S Nielsen; L R Lund; F Blasi; K Danø
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

6.  Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.

Authors:  K W Rodenburg; L Kjoller; H H Petersen; P A Andreasen
Journal:  Biochem J       Date:  1998-01-01       Impact factor: 3.857

7.  Plasminogen activator inhibitor (type-1) in rat adrenal medulla.

Authors:  J Eriksen; P Kristensen; C Pyke; K Danø
Journal:  Histochemistry       Date:  1989

8.  The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.

Authors:  Niels Behrendt; Karin List; Peter A Andreasen; Keld Danø
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

9.  A novel mode of intervention with serine protease activity: targeting zymogen activation.

Authors:  Grant E Blouse; Kenneth A Bøtkjaer; Elena Deryugina; Aleksandra A Byszuk; Janni M Jensen; Kim K Mortensen; James P Quigley; Peter A Andreasen
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

10.  The regulatory region of the human plasminogen activator inhibitor type-1 (PAI-1) gene.

Authors:  A Riccio; L R Lund; R Sartorio; A Lania; P A Andreasen; K Danø; F Blasi
Journal:  Nucleic Acids Res       Date:  1988-04-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.